Akero Therapeutics Stock Price, News & Analysis

Akero Therapeutics (Nasdaq: AKRO) agreed to be acquired by Novo Nordisk for up to $5.2 billion in cash on Oct 9, 2025. Shareholders will receive $54.00 per share in cash at closing plus a non-transferable CVR entitling holders to $6.00 per share if efruxifermin (EFX) receives full U.S. approval for compensated cirrhosis due to MASH by June 30, 2031.

The upfront cash equals ~$4.7 billion (a 19% premium to Akero 30-day VWAP and 42%+ premium to the May 19, 2025 closing price). Combined upfront and CVR represent a ~$5.2 billion equity value (a 32% premium to 30-day VWAP and 57%+ premium to May 19, 2025 close). Transaction approved by Akero board; expected to close around year-end pending shareholder and regulatory approvals.

Akero Therapeutics (NASDAQ: AKRO) announced two oral presentations and one poster at the 76th AASLD The Liver Meeting® 2025 in Washington, DC, Nov 7-11, 2025. Presentations will report 96-week data for efruxifermin (EFX) from the Phase 2b SYMMETRY study in compensated cirrhosis (F4c) due to MASH and AI-powered histology results from the Phase 2b HARMONY study in pre-cirrhotic (F2-F3) MASH.

Oral sessions are scheduled Nov 9, 2025 at 12:00 PM ET and 2:45 PM ET; the poster session is Nov 10, 2025 from 11:30 AM-12:30 PM ET.

Akero Therapeutics (NASDAQ:AKRO), a clinical-stage biotechnology company focused on developing treatments for serious metabolic diseases, has announced its participation in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference.

The presentation is scheduled for September 8, 2025, at 10:45 a.m. E.T. in New York. Investors can access the live webcast through Akero's investor relations website, with an archived replay available after the event.

Akero Therapeutics (Nasdaq: AKRO) published 96-week results from its Phase 2b HARMONY trial in The Lancet, evaluating efruxifermin (EFX) in patients with pre-cirrhotic MASH. The trial demonstrated significant efficacy with 49% of patients receiving 50mg EFX achieving at least one stage fibrosis improvement compared to 19% for placebo.

Key findings include 40% and 37% of patients achieving MASH resolution in the 28mg and 50mg groups respectively, versus 19% for placebo. The composite endpoint of MASH resolution and fibrosis improvement was met by 35% and 28% of participants in the 50mg and 28mg groups. Notably, 92% of week 24 responders maintained their response at week 96.

EFX was generally well-tolerated, with mainly mild to moderate gastrointestinal events reported. The results support EFX's potential to reduce disease progression in MASH patients.

Akero Therapeutics (Nasdaq: AKRO) reported significant progress in its clinical programs for EFX, a potential first- and best-in-class therapy for MASH (Metabolic dysfunction-Associated SteatoHepatitis). The company's 96-Week Phase 2b SYMMETRY trial results were published in the New England Journal of Medicine, demonstrating statistically significant reversal of compensated cirrhosis in MASH patients.

At EASL 2025, three presentations highlighted EFX's anti-fibrotic activity across all MASH stages. The data showed promising results in high-risk patient subgroups, including those with cryptogenic cirrhosis and type 2 diabetes. New analyses from the HARMONY study confirmed consistent fibrosis improvement in pre-cirrhotic MASH patients using both conventional and AI-based analysis methods.

Financially, Akero reported $1.09 billion in cash and equivalents as of June 30, 2025, expected to fund operations into 2028. Q2 operating expenses increased to $80.9 million, up from $65.7 million in the previous year, primarily due to ongoing Phase 3 trials.

Akero Therapeutics (NASDAQ: AKRO), a clinical-stage biotechnology company focused on developing treatments for serious metabolic diseases, has announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference. The company's management will deliver a presentation on Tuesday, June 10, 2025, at 2:40 p.m. ET. Interested parties can access the live webcast through the investor relations section of Akero's website at www.akerotx.com. An archived recording of the presentation will be made available on the company's website following the live event.

Akero Therapeutics (Nasdaq: AKRO), a clinical-stage biotechnology company focused on developing treatments for serious metabolic diseases, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's management will deliver a presentation on Wednesday, June 4, 2025, at 8:45 a.m. Pacific Time. Investors and interested parties can access the live webcast through Akero's investor relations website section at www.akerotx.com, with an archived replay available after the event.

Akero Therapeutics (NASDAQ: AKRO) reported significant Q1 2025 results, highlighted by groundbreaking Phase 2b SYMMETRY study outcomes showing statistically significant reversal of cirrhosis in MASH patients after 96 weeks of efruxifermin (EFX) treatment. Key findings include 39% of patients in the 50mg EFX group showing ≥1-stage fibrosis improvement, representing a 24% effect size over placebo. The company strengthened its financial position with a $402.5M follow-on offering, ending Q1 with $1.13B in cash reserves. Operating expenses increased to $80.9M, up from $60.0M in Q1 2024. The Phase 3 SYNCHRONY program continues to advance, with preliminary results from Real-World study expected in H1 2026. The SYMMETRY results were published in the New England Journal of Medicine and presented at EASL 2025, highlighting EFX's potential as a first- and best-in-class therapy for MASH treatment.

Akero Therapeutics (NASDAQ: AKRO) presented new analyses of their Phase 2b HARMONY trial for efruxifermin (EFX) in pre-cirrhotic MASH patients at EASL Congress 2025. The study utilized HistoIndex's AI-based qFibrosis® digital pathology analysis alongside conventional methods. Key findings showed that among patients treated with 50mg EFX, over 50% were classified as responders across all three endpoints (qFibrosis®, ELF test score, and FibroScan®), compared to less than 5% in the placebo group. At Week 96, the 50mg EFX group (N=26) showed similar response rates between conventional pathology (77%) and qFibrosis® (81%). Notably, qFibrosis® detected more responders at Week 24 (18 patients) compared to conventional pathology (10 patients), suggesting earlier detection of treatment response.